acyl-CoA synthetase bubblegum family member 2Genealiases: BGR · BRGL · PRTD-NY3 · PRTDNY3
Q-omics provides the consensus-scored ACSBG2 profile across patient tissues and cancer cell-line models. ACSBG2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ACSBG2 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ACSBG2 RNA expression shows 18,247 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRP, and THYM as cancer lineages where ACSBG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACSBG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACSBG2 survival associations across molecular data types. ACSBG2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACSBG2 RNA expression–survival associations across cancer types. High ACSBG2 expression shows unfavorable associations in MESO, KICH and ACC, but favorable associations in HNSC, BRCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ACSBG2 RNA expression.
This table summarizes ACSBG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ACSBG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACSBG2 shows lower tumor expression in KIRP, KIRC, BRCA and KICH and higher tumor expression in HNSC and LIHC. The KIRP box plot shows higher ACSBG2 RNA expression in normal versus tumor tissue (log2 FC = −0.987, t-test p < 0.001).
This table shows molecular features associated with ACSBG2 in patient tissues and cancer cell lines. In patient samples, ACSBG2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ACSBG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and SOFT_TISSUE.
